Scientists at Tyumen State University have discovered a universal natural antibiotic – emericillipsin-a, that overcomes the resistance of pathogens to drugs. The authors of the discovery report it in a study published in the journal Applied Biochemistry and Microbiology.
One of the tasks of pharmacology today, as noted in the article by Tyumen scientists, is to search for natural antibiotics that can fight microorganisms with multi-drug resistant (MDR) or absolute (extreme-drug resistant, XDR) resistance to antibiotics available on the market.
For the first time in the world, researchers from Tyumen State University demonstrated the unique ability of the peptide emericillipsin-A, isolated from the alkalophilic mycelial fungus Emericellopsis alkalina. Also, according to experts, the substance inhibits the ability of bacteria to form biofilms. Thus, it makes the resistance of these pathogens to antibiotics disappear.
The primary therapeutic feature of the studied substance is the versatility of the effect. In short, MDR and XDR forms of bacteria are defenceless against emericillipsin-A. Moreover, it defeats practically any pathogenic eukaryotes, for example, mycelial fungi and yeast.
“Emericillipsin-A acts on eukaryotes as well as prokaryotes through different molecular mechanisms. Eukaryotes – fungi and tumour cells – die due to the destruction of their cell membrane by the peptide. Further, prevention of biofilms formation suppresses the virulence of prokaryotes” – Evgeny Rogozhin, a senior researcher at the X-BIO laboratory of antimicrobial resistance at the TSU, said.
Bacillus subtilis is a probiotic bacteria strain to support natural defences. It has immunostimulant properties, improving natural defences, helps in the fight against infections and external aggressions and may boost immunity in older people and protect them from winter infections.
As noted by the authors of the study, among the pathologies that emericillipsin-A will allow to fight are tumours. Besides, it will defeat all kinds of bacterial and fungal infections.
Emericillipsin-A is promising both as an independent therapeutic agent and as an element of elaborate preparations. Therapy can be carried out either by injection or topically by direct treatment of the affected tissue.
The study was carried out in close collaboration with colleagues from the V.I. G.F. Gause, Central Research Institute of Epidemiology of Rospotrebnadzor and Institute of Bioorganic Chemistry. M.M. Shemyakin and Yu.A. Ovchinnikov RAS.
In the future, the team of scientists intends to move from working with cellular models to laboratory testing of the drug.
Recall that the Ministry of Health warned that the unlimited prescription of antibiotics could soon lead to the fact that none of the existing antibacterial drugs will work.
Colon irrigation and comprehensive consultation with professional colon hydrotherapist registered with RICTAT and ARCH at the Parkland Clinic in Holborn. The best colonic hydrotherapy deal in London.